Agios Pharmaceuticals, Inc. (AGIO)
After hours:
| Previous Close | 33.22 |
| Open | 33.47 |
| Bid | 32.76 x 200 |
| Ask | 32.84 x 200 |
| Day's Range | 32.52 - 33.51 |
| 52 Week Range | 19.80 - 35.50 |
| Volume | |
| Avg. Volume | 775,206 |
| Market Cap | 1.862B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.31 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.00 |
GlobeNewswireAgios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of
Simply Wall St.Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investors in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) had a good week, as its shares rose 9.7% to close at US$34.54...
ZacksAgios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
